NASDAQ$SMTI

Sanara MedTech Inc · Q2 2024 earnings

Q2 2024 earnings · · Investor relations

Briefing

Sanara MedTech reported eleventh consecutive record revenue quarter, driven by strong sales in the surgical team and supported by all functional areas, while also strengthening the senior management team.

Sanara MedTech reported a record revenue quarter with a 28% increase compared to the previous year, driven by increased sales of soft tissue repair products and market penetration. However, the company experienced a net loss due to increased SG&A costs, executive separation costs, acquisition costs, and higher amortization expenses.

  • Generated net revenue of $20.2 million, a 28% increase from the prior year period.
  • The number of facilities where products were sold grew to 800+ compared to 600+ in the same quarter last year.
  • Reported a net loss of $3.5 million, compared to a net loss of $1.9 million for the prior year quarter.
  • Generated Adjusted EBITDA of $0.6 million, compared to Adjusted EBITDA of ($0.3) million for the prior year quarter.

Headline financials

Total Revenue

$20.2M

Previous: $15.8M+28.0%
EPS (adj)

-$0.41

Previous: -$0.22-86.4%
Capital Expenditures

-$125K

Previous: -$40.7K-206.5%
Free Cash Flow

-$3.63M

Previous: -$1.87M-94.2%
Net Income

-$3.5M

Previous: -$1.83M-91.7%
Operating Income

-$2.88M

Previous: -$1.87M-54.6%
Gross Profit

$18.2M

Previous: $13.6M+33.8%
Cash & Equivalents

$6.15M

Previous: $6.06M+1.5%
Total Assets

$73.4M

Previous: $58.3M+25.9%
R&D Expense

$986K

No prior period
Stock-Based Comp

$1.41M

Previous: $1.13M+25.2%

Revenue & EPS history

Sanara MedTech · Revenue · Quarterly

$20.2M

Q2 2024+28%vs Q2 2023
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Revenue by segment

Sanara MedTech · $31.6M total across 2 segments · Q2 2023

  • Soft tissue repair
    $15.8M
  • Bone fusion products
    $15.8M

Forward guidance

No specific forward guidance was provided in the press release.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q2 2024

Historical avgQ2 2024

+0.2%

Avg return

Earnings day

-2.3%

Avg return

5 days after

+1.0%

Avg return

30 days after

34%

22 / 64 earnings

Positive

+28.6%

Q4 2014

Best reaction

-25.0%

Q3 2010

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+13.0%+17.3%
Q4 2025-0.3%-7.5%+4.3%
Q3 2025-23.4%-24.9%-7.6%
Q1 2025-9.0%-11.2%-17.9%
Q4 2024-12.6%-15.4%-10.4%
Q3 2024+6.3%-1.0%+2.5%
Q2 2024+14.9%+16.3%+20.2%
Q1 2024-5.0%-2.9%-0.5%
Q4 2023-1.8%-1.1%-13.1%
Q3 2023+18.8%+15.3%+37.5%
Q2 2023-12.5%-13.6%-22.6%
Q1 2023-5.0%-9.2%-5.9%
Q4 2022-0.1%-4.1%+17.9%
Q3 2022+4.1%+7.2%+3.2%
Q2 2022+1.2%-1.7%+13.4%
Q1 2022+5.0%+2.3%-12.2%
Q4 2021+2.5%+10.7%-10.9%
Q3 2021-1.6%-2.2%-15.8%
Q2 2021-8.3%-12.4%-14.5%
Q1 2021+5.2%+14.9%+28.7%
Q4 2020+14.5%+6.8%-4.5%
Q3 2020-4.5%-4.3%+15.7%
Q2 2020+9.8%+13.7%+37.2%
Q1 2020-20.7%-18.2%+28.8%
Q4 2019-4.3%+7.3%+30.9%
Q3 2019-3.9%-5.7%+5.1%
Q2 2019-11.5%-20.1%-17.2%
Q1 2019+0.0%-16.7%-16.7%
Q4 2018+0.0%-16.7%-16.7%
Q3 2018+0.0%+0.0%+0.0%
Q2 2018-10.0%-10.0%-30.0%
Q1 2018+20.0%+0.0%+20.0%
Q4 2017+20.0%+0.0%+20.0%
Q3 2017+0.0%+0.0%-14.3%
Q2 2017+0.0%+16.7%+16.7%
Q1 2017+0.0%+0.0%-22.2%
Q4 2016+0.0%+0.0%-10.0%
Q3 2016-20.0%-20.0%+0.0%
Q2 2016+20.0%+0.0%+0.0%
Q1 2016+0.0%
Q4 2015+0.0%
Q3 2015+0.0%
Q2 2015+0.0%
Q1 2015+11.1%
Q4 2014+28.6%
Q3 2014+0.0%
Q2 2014+0.0%
Q1 2014+0.0%
Q4 2013+0.0%
Q3 2013+14.3%
Q2 2013+0.0%
Q1 2013+16.7%
Q4 2012-12.5%
Q3 2012-16.7%
Q2 2012+6.7%
Q1 2012+0.0%
Q4 2011-4.3%
Q3 2011+0.0%
Q2 2011-10.3%
Q1 2011-11.1%
Q4 2010+3.1%
Q3 2010-25.0%
Q2 2010+2.9%
Q1 2010+5.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro